Eagle Pharmaceuticals Management
Management criteria checks 3/4
Eagle Pharmaceuticals' CEO is Mike Graves, appointed in Jan 2023, has a tenure of 1.25 years. directly owns 0.08% of the company’s shares, worth $43.93K. The average tenure of the management team and the board of directors is 1.8 years and 7.4 years respectively.
Key information
Mike Graves
Chief executive officer
US$391.0k
Total compensation
CEO salary percentage | n/a |
CEO tenure | 1.3yrs |
CEO ownership | 0.08% |
Management average tenure | 1.8yrs |
Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?
Sep 21Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
Jul 13Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly
Jun 21These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Oct 27Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia
Oct 12Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose
Sep 27Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court
Aug 18Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be
Aug 15Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M
Aug 09These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Jul 06Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price
Apr 29Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?
Dec 16Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package
Jul 06Eagle Pharmaceuticals: A Potential Reopening Play
Jun 16Eagle Pharmaceuticals EPS misses by $0.49, misses on revenue
May 10Eagle Pharma's Treakisym RTD + rituximab OK'd in Japan for large b-cell lymphoma
Apr 30Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt
Apr 15Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price
Mar 25CEO
Mike Graves (60 yo)
1.3yrs
Tenure
US$391,026
Compensation
Mr. Michael Graves, also known as Mike, is Interim Principal Executive Officer of Eagle Pharmaceuticals, Inc. from 2023. He had been the Independent Chairman of Eagle Pharmaceuticals Inc. since June 2016 u...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Interim Principal Executive Officer & Executive Chairman of the Board | 1.3yrs | US$391.03k | 0.080% $ 43.9k | |
Interim CFO | less than a year | US$331.03k | 0.21% $ 116.0k | |
Executive VP | 6.9yrs | no data | no data | |
Senior Vice President of Clinical Drug Development | 3.4yrs | no data | no data | |
Senior Vice President of Pharmaceutical Development | 3.4yrs | no data | no data | |
Senior VP & Head of Commercial | 1.8yrs | no data | no data | |
Executive Vice President of Oncology Business Development | 1.3yrs | no data | no data |
1.8yrs
Average Tenure
60yo
Average Age
Experienced Management: EGRX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Interim Principal Executive Officer & Executive Chairman of the Board | 10.4yrs | US$391.03k | 0.080% $ 43.9k | |
Interim CFO | 17.1yrs | US$331.03k | 0.21% $ 116.0k | |
Independent Director | 7.1yrs | US$312.28k | 0.17% $ 95.8k | |
Independent Director | 7.8yrs | US$324.78k | 0% $ 0 | |
Lead Independent Director | 4.7yrs | US$308.53k | 0% $ 0 | |
Independent Director | 3yrs | US$308.53k | 0% $ 0 |
7.4yrs
Average Tenure
60.5yo
Average Age
Experienced Board: EGRX's board of directors are considered experienced (7.4 years average tenure).